The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co.’s cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday. Bristol-Myers, which initially said a decision was expected by Aug. 27, said it had submitted additional clinical-trial data, which amounts to a “Major amendment” that requires additional time […]

Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system’s attack. Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first […]

New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. The growing reluctance of governments and private insurers to fund very expensive drugs – even remarkably effective ones – points to a showdown […]

French drugmaker Sanofi (SASY.PA) said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals (REGN.O) in the hot area of cancer immunotherapy. Sanofi will make an upfront payment of $640 million to Regeneron and the U.S. biotech company will get up to $375 million more if certain […]

DUBLIN, IRELAND–(Marketwired – Jul 27, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms […]